Minoxidil topique 2 % face à Minoxidil topique 0,1 %
1 essai les comparent directement, sur les mêmes patients. Voir Minoxidil topique 2 % · Voir Minoxidil topique 0,1 %
Chez 100 hommes de 23 à 49 ans atteints de calvitie du vertex, un seul essai de fiabilité limitée (Olsen 1986) a comparé deux concentrations de minoxidil topique. À 26 semaines, la lotion à 2 % fait nettement mieux que celle à 0,1 % : +175 cheveux gagnés sur une zone test de 5,1 cm² contre +92. Pour les cheveux épais, l'avantage va aussi au 2 % (+190 contre +81), sans que cet écart soit testé. Ce résultat repose sur un seul essai.
Olsen 1986
Essai randomisé, risque de biais élevé. Dose-response study of topical minoxidil in male pattern baldness.
| Critère | Minoxidil topique 2 % | Minoxidil topique 0,1 % | Écart |
|---|---|---|---|
| Gain de cheveux (cercle d'un pouce, 5,1 cm²) | +175 cheveux sur 5,1 cm²Voir la citationTable III. Change from baseline target area hair Change from base- line target area hair Placebo 0.01% counts (N = 18) (N -- lS) Vellus (_SD) 9 (-+89) 37 (---59) Range - 154~. 195 -55, 164 Nonvellus (-+SD) 81 (---95) 48 (+57) Range -37,251 -52, 162 Total (__SD) 90 (___89) 84 (+-69) Range -40, 286 -21, 161 SD: Standard deviation. Citation complémentaire (methode) thus conservative. Univariate analyses were inspected for differences between dose levels with the use of Duncan's multiple range test at a significance level of 0.05. In addition, X2 tests were used to evaluate dif- Citation complémentaire (significativite) sis, the changes in (log) total and (log) nonvellus hair counts were significantly associated with treat- ment group (p = 0.04 and 0.02, respectively; Table III). The change from baseline vellus hair counts were not significantly associated with treat- ment group (p = 0.43). Duncan's multiple range test indicated that, for (log) total hair counts, the 2% minoxidil treatment group results were signif- icantly greater than the 0.01% and 0.1% topical minoxidil and placebo groups. The nonvellus (log) count was also significantly greater for the 2% topical minoxidil group than for the 0.01% topical minoxidil and placebo groups. There was no sta- tistically significant difference between the 2% and 1% topical minoxidil groups in terms of mean change in nonvellus or total hair counts from base- line to the end of this study. Citation complémentaire (valeur) counts relative to treatment group Treatment group Topical minoxidil 2% 0.1% I 1% (N = 15) (N = 15) (N = 17) 11 (±87) -31 (+_92) -15 (+_ 121) - 184, 123 -245, 58 -342, 176 81 (_+68) 180 (_+ 126) 190 (___ 136) -32, 267 27, 395 38, 551 92 (-+79) 149 (+93) 175 (+99) -30, 209 15,362 38, 347 Olsen EA, DeLong ER, Weiner MS. Dose-response study of topical minoxidil in male pattern baldness.. J Am Acad Dermatol 1986, DOI 10.1016/s0190-9622(86)70138-2. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | +92 cheveux sur 5,1 cm²Voir la citationTable III. Change from baseline target area hair Change from base- line target area hair Placebo 0.01% counts (N = 18) (N -- lS) Vellus (_SD) 9 (-+89) 37 (---59) Range - 154~. 195 -55, 164 Nonvellus (-+SD) 81 (---95) 48 (+57) Range -37,251 -52, 162 Total (__SD) 90 (___89) 84 (+-69) Range -40, 286 -21, 161 SD: Standard deviation. Citation complémentaire (methode) thus conservative. Univariate analyses were inspected for differences between dose levels with the use of Duncan's multiple range test at a significance level of 0.05. In addition, X2 tests were used to evaluate dif- Citation complémentaire (significativite) sis, the changes in (log) total and (log) nonvellus hair counts were significantly associated with treat- ment group (p = 0.04 and 0.02, respectively; Table III). The change from baseline vellus hair counts were not significantly associated with treat- ment group (p = 0.43). Duncan's multiple range test indicated that, for (log) total hair counts, the 2% minoxidil treatment group results were signif- icantly greater than the 0.01% and 0.1% topical minoxidil and placebo groups. The nonvellus (log) count was also significantly greater for the 2% topical minoxidil group than for the 0.01% topical minoxidil and placebo groups. There was no sta- tistically significant difference between the 2% and 1% topical minoxidil groups in terms of mean change in nonvellus or total hair counts from base- line to the end of this study. Citation complémentaire (valeur) counts relative to treatment group Treatment group Topical minoxidil 2% 0.1% I 1% (N = 15) (N = 15) (N = 17) 11 (±87) -31 (+_92) -15 (+_ 121) - 184, 123 -245, 58 -342, 176 81 (_+68) 180 (_+ 126) 190 (___ 136) -32, 267 27, 395 38, 551 92 (-+79) 149 (+93) 175 (+99) -30, 209 15,362 38, 347 Olsen EA, DeLong ER, Weiner MS. Dose-response study of topical minoxidil in male pattern baldness.. J Am Acad Dermatol 1986, DOI 10.1016/s0190-9622(86)70138-2. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Probablement réel |
| Gain de cheveux non-duvet (cercle d'un pouce, 5,1 cm²) | +190 cheveux sur 5,1 cm²Voir la citationTable III. Change from baseline target area hair Change from base- line target area hair Placebo 0.01% counts (N = 18) (N -- lS) Vellus (_SD) 9 (-+89) 37 (---59) Range - 154~. 195 -55, 164 Nonvellus (-+SD) 81 (---95) 48 (+57) Range -37,251 -52, 162 Total (__SD) 90 (___89) 84 (+-69) Range -40, 286 -21, 161 SD: Standard deviation. Citation complémentaire (methode) thus conservative. Univariate analyses were inspected for differences between dose levels with the use of Duncan's multiple range test at a significance level of 0.05. In addition, X2 tests were used to evaluate dif- Citation complémentaire (significativite) sis, the changes in (log) total and (log) nonvellus hair counts were significantly associated with treat- ment group (p = 0.04 and 0.02, respectively; Table III). The change from baseline vellus hair counts were not significantly associated with treat- ment group (p = 0.43). Duncan's multiple range test indicated that, for (log) total hair counts, the 2% minoxidil treatment group results were signif- icantly greater than the 0.01% and 0.1% topical minoxidil and placebo groups. The nonvellus (log) count was also significantly greater for the 2% topical minoxidil group than for the 0.01% topical minoxidil and placebo groups. There was no sta- tistically significant difference between the 2% and 1% topical minoxidil groups in terms of mean change in nonvellus or total hair counts from base- line to the end of this study. Citation complémentaire (valeur) counts relative to treatment group Treatment group Topical minoxidil 2% 0.1% I 1% (N = 15) (N = 15) (N = 17) 11 (±87) -31 (+_92) -15 (+_ 121) - 184, 123 -245, 58 -342, 176 81 (_+68) 180 (_+ 126) 190 (___ 136) -32, 267 27, 395 38, 551 92 (-+79) 149 (+93) 175 (+99) -30, 209 15,362 38, 347 Olsen EA, DeLong ER, Weiner MS. Dose-response study of topical minoxidil in male pattern baldness.. J Am Acad Dermatol 1986, DOI 10.1016/s0190-9622(86)70138-2. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | +81 cheveux sur 5,1 cm²Voir la citationTable III. Change from baseline target area hair Change from base- line target area hair Placebo 0.01% counts (N = 18) (N -- lS) Vellus (_SD) 9 (-+89) 37 (---59) Range - 154~. 195 -55, 164 Nonvellus (-+SD) 81 (---95) 48 (+57) Range -37,251 -52, 162 Total (__SD) 90 (___89) 84 (+-69) Range -40, 286 -21, 161 SD: Standard deviation. Citation complémentaire (valeur) counts relative to treatment group Treatment group Topical minoxidil 2% 0.1% I 1% (N = 15) (N = 15) (N = 17) 11 (±87) -31 (+_92) -15 (+_ 121) - 184, 123 -245, 58 -342, 176 81 (_+68) 180 (_+ 126) 190 (___ 136) -32, 267 27, 395 38, 551 92 (-+79) 149 (+93) 175 (+99) -30, 209 15,362 38, 347 Olsen EA, DeLong ER, Weiner MS. Dose-response study of topical minoxidil in male pattern baldness.. J Am Acad Dermatol 1986, DOI 10.1016/s0190-9622(86)70138-2. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Non testé |